Vivos Inc. income statement RDGL

In fiscal 2025, which ended Dec 31, 2025, Vivos Inc. reported revenue of $68,379, up 144.3% from the year before. It recorded a net loss of $3.1 million. The operating loss came to $3.2 million, an operating margin of -4628.7%. Diluted earnings per share were -$0.01. Over the twelve months ended Jun 30, 2026, revenue was $99,099 and the net loss was $3.6 million. Across the 8 fiscal years shown, revenue grew from $4,054 in fiscal 2017 to $68,379 in fiscal 2025, about 49.7% a year.

USD in millions, except per-share amounts and margins. The percent under a figure is the change from the year before.

Line
FY 2026
Jun 30, 2026
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
FY 2019
Dec 31, 2019
FY 2018
Dec 31, 2018
FY 2017
Dec 31, 2017
FY 2016
Dec 31, 2016
Revenue
0
+91.5%
0
+144.3%
0
+43.6%
0
-46.6%
0
+145.2%
0
+112.7%
0
-26.3%
0
+134.3%
—
0
—
Cost of revenue
0
+25.0%
0
+313.6%
0
+21.3%
0
-11.3%
0
+139.8%
0
+114.0%
0
-7.0%
0
—
—
0
Gross profit
-0
+46.6%
-0
-1902.5%
-0
+50.6%
-0
-178.2%
0
+167.4%
0
+107.4%
0
-59.9%
0
—
—
—
Research and development
0
-46.3%
0
+8.5%
0
-55.7%
1
+113.1%
0
+19.9%
0
+238.8%
0
+25.3%
0
-35.1%
0
-48.7%
0
-38.1%
0
+119.2%
Selling, general and administrative
0
+2.6%
0
+22.6%
0
+45.9%
0
+9.7%
0
+34.9%
0
+2.8%
0
+27.0%
0
-24.6%
0
-50.2%
0
-69.1%
1
+75.0%
Operating income
-3
+7.1%
-3
-21.5%
-3
+6.8%
-3
-10.9%
-3
-0.6%
-3
-272.0%
-1
+49.4%
-1
+46.6%
-2
+4.9%
-3
+41.0%
-4
-117.3%
Other income (expense)
-1
-171.2%
0
+132.4%
-0
-201.2%
-0
-313.5%
0
+283.3%
-0
+90.9%
-0
-1.6%
-0
+94.6%
-5
-37.1%
-4
+29.8%
-5
-165.5%
Pretax income
-4
-8.2%
-3
-5.3%
-3
-0.5%
-3
-17.2%
-2
+2.3%
-3
-164.1%
-1
+40.6%
-2
+79.1%
-8
-20.0%
-6
+34.9%
-10
-258.1%
Income tax
—
—
—
—
—
0
—
—
—
—
0
Net income
-4
-8.2%
-3
-5.3%
-3
-0.5%
-3
-17.2%
-2
+2.3%
-3
-164.1%
-1
+40.6%
-2
+79.1%
-8
-20.0%
-6
+34.9%
-10
-258.1%
Basic EPS
-0.01
-1.5%
-0.01
+0.0%
-0.01
+0.0%
-0.01
+0.0%
-0.01
—
—
—
—
—
—
Diluted EPS
-0.01
-1.5%
-0.01
+0.0%
-0.01
+0.0%
-0.01
—
—
—
—
—
—
—
Weighted average shares, basic
465
+6.6%
453
+10.5%
410
+11.1%
369
+4.9%
351
+7.8%
326
+46.3%
223
+27.2%
175
—
—
—
Weighted average shares, diluted
465
+6.6%
453
+10.5%
410
+11.1%
369
—
—
—
—
—
—
—
Other measures
Depreciation and amortization
—
0
—
—
—
—
—
—
0
—
0
-32.0%
EBITDA
—
-3
—
—
—
—
—
—
-2
—
-4
-117.7%
Interest coverage
—
—
—
—
-99.22x
—
-2.34x
-5.09x
-0.44x
-0.67x
-0.71x
Margins
Gross margin
-25.89%
-87.39%
-10.66%
-30.95%
21.15%
19.39%
19.89%
36.55%
—
—
—
Operating margin
-2,852.46%
-4,628.68%
-9,303.03%
-14,323.83%
-6,898.13%
-16,805.25%
-9,607.44%
-13,999.78%
—
-64,551.41%
—
Pretax margin
-3,633.58%
-4,483.86%
-10,396.31%
-14,844.89%
-6,767.75%
-16,979.69%
-13,671.31%
-16,948.39%
—
-158,330.71%
—
Profit margin
-3,633.58%
-4,483.86%
-10,396.31%
-14,844.89%
-6,767.75%
-16,979.69%
-13,671.31%
-16,948.39%
—
-158,330.71%
—
EBITDA margin
—
-4,628.14%
—
—
—
—
—
—
—
—
—
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except per-share amounts and margins. Weighted average shares are in millions. Interest expense and finance costs are positive costs. A negative amount on a gain (loss) or income (expense) line is a loss or an expense. EBITDA is operating income plus depreciation and amortization. Interest coverage is operating income divided by interest expense. The first column is the trailing twelve months through the latest quarter. More on our methodology.

Company profile

Industry
Surgical & Medical Instruments & Apparatus (SIC 3841)
Listed as
RDGL (OTC)
Fiscal year ends
December 31
Incorporated in
DE
Headquarters
Richland, WA
SEC filer status
Non-accelerated filer, Smaller reporting company
SEC CIK
1449349
Former names
ADVANCED MEDICAL ISOTOPE Corp (until Dec 18, 2017)

Other Surgical & Medical Instruments & Apparatus companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.